VAPAWAY.EU - Research and education on VAP prevention
  • Home
  • Articles
  • GuideLines
  • Links
  • About VAPAWAY
  • Training
  • Contacts

Login








Lost Password?

Register to receive updated data on VAPAWAY initiative

Agenda

 

9 - 12 March 2010

ISICEM International Symposium on Intensive Care and Emergency Medicine - Brussels (Belgium)

ISICEM

 

9 -11 June 2010

EACTA European Association of Cardiothoracic Anaesthesiologists - Edinburgh (UK)

EACTA

 

12-15 June 2010

ESA European Society of Anaesthesiology - Helsinki (Finland)

ESA

 

18-22 September 2010

ERS European Respiratory Society - Barcellona (Spain)

ERS

 

9 -13 October 2010

ESICM European Society of Intensive Care Medicine - Barcellona (Spain)

ESICM

  

 

> International events   

> Local events 

PREDICTING THE RISK OF DOCUMENTED VAP FOR BENCHMARKING:CONSTRUCTION AND VALIDATION OF A SCORE PDF Print E-mail
Monday, 01 February 2010
Zahar JR, Nguile-Makao M, Français A, Schwebel C, Garrouste-Orgeas M, Goldgran-Toledano D, Azoulay E, Thuong M, Jamali S, Cohen Y, de Lassence A, Timsit JF.
Microbiology and Infection Control Unit (J-RZ), Necker Teaching Hospital, Paris France. 
Crit Care Med. 2009 Sep;37(9):2545-51. Comment in: Crit Care Med. 2009 Sep;37(9):2657-9.

OBJECTIVES:: To build and validate a ventilator-associated pneumonia risk score for benchmarking. The rate of ventilator-associated pneumonia varies widely with case-mix, a fact that has limited its use for measuring intensive care unit performance.

METHODS:: We studied 1856 patients in the OUTCOMEREA database treated at intensive care unit admission by endotracheal intubation followed by mechanical ventilation for >48 hrs; they were allocated randomly to a training data set (n = 1233) or a validation data set (n = 623). Multivariate logistic regression was used. Calibration of the final model was assessed in both data sets, using the Hosmer-Lemeshow chi-square test and receiver operating characteristic curves.

MEASUREMENTS AND MAIN RESULTS:: Independent risk factors for ventilator-associated pneumonia were male gender (odds ratio = 1.97, 95% confidence interval = 1.32-2.95); SOFA at intensive care unit admission (<3 [reference value], 3-4 [2.57, 1.39-4.77], 5-8 [7.37, 4.24-12.81], >8 [5.81 (3.2-10.52)], no use within 48 hrs after intensive care unit admission of parenteral nutrition (2.29, 1.52-3.45), no broad-spectrum antimicrobials (2.11, 1.46-3.06); and mechanical ventilation duration (<5 days (); 5-7 days (17.55, 4.01-76.85); 7-15 days (53.01, 12.74-220.56); >15 days (225.6, 54.3-936.7). Tests in the training set showed good calibration and good discrimination (area under the curve-receiver operating characteristic curve = 0.881), and both criteria remained good in the validation set (area under the curve-receiver operating characteristic curve = 0.848) and good calibration (Hosmer-Lemeshow chi-square = 9.98, p = .5). Observed ventilator-associated pneumonia rates varied across intensive care units from 9.7 to 26.1 of 1000 mechanical ventilation days but the ratio of observed over theoretical ventilator-associated pneumonia rates was >1 in only two intensive care units.

CONCLUSIONS:: The ventilator-associated pneumonia rate may be useful for benchmarking provided the ratio of observed over theoretical rates is used. External validation of our prediction score is needed.

 
< Prev   Next >
Select and watch
from the following webinars

 


Join us on www.smartonweb.org

Partner

VAPAWAY is proudly supported by Covidien.

http://www.covidien.com